Tumor-infiltrating CD4 þ CD25 þ regulatory T cells (Tregs) are associated with an impaired prognosis in several cancers. The transcription factor forkhead box P3 (Foxp3) is generally expressed in Tregs. Here, we identify and characterize spontaneous cytotoxic immune responses to Foxp3-expressing cells in peripheral blood of healthy volunteers and cancer patients. These immune responses were directed against a HLA-A2-restricted peptide epitope derived from Foxp3. Foxp3-reactive T cells were characterized as cytotoxic CD8 þ T cells. These cells recognized dendritic cells incubated with recombinant Foxp3 protein indicating that this protein was indeed internalized, processed and cross-presented in the context of HLA-A2. More importantly, however, Foxp3-specific T cells were able to specifically recognize Tregs. Similarly, Foxp3 þ malignant T cells established from a Cutaneous T-cell lymphomas (CTCL) patient were readily killed by the Foxp3-specific cytotoxic T lymphocytes. The spontaneous presence of Foxp3-specific cytotoxic T-cell responses suggest a general role of such T cells in the complex network of immune regulation as such responses may eliminate Tregs, that is, suppression of the suppressors. Consequently, induction of Foxp3-specific cytotoxic T-cell responses appears as an attractive tool to boost spontaneous or therapeutically provoked immune responses, for example, for the therapy of cancer.
INTRODUCTION
Since the rediscovery of suppressor T cells as CD4 þ CD25 þ regulatory T cells (Tregs), this cell subset has become an intense focus of immunological research. 1 Tregs are an important component in this complex network of cells responsible for self-tolerance and immune homeostasis. Tregs either develop in the thymus or can be converted in the periphery by, for example, exposure to transforming growth factor-b. Both 'natural' and 'inducible' Tregs utilize similar mechanisms to mediate immune suppression: (i) secretion of immune suppressive cytokines, for example, transforming growth factor-b, interleukin (IL) -35 and IL-10; (ii) direct killing of effector T cells; (iii) metabolic commotion, for example, IL-2 deprivation; and (iv) modulation of antigen-presenting cells by binding of cytotoxic T-lymphocyte antigen-4 to CD80/86. 2 The deficiency and/or altered function of Tregs are associated with autoimmunity. 3 Notably, both natural and induced Tregs express the transcription factor forkhead box P3 (Foxp3). 1 Additional phenotypic characteristics of Tregs include high expression of the Il-2 receptor a-chain (CD25), the glucocorticoid-induced TNFR family related gene and cytotoxic T-lymphocyte antigen-4 as well as low expression of CD127 (3) (4) (5) . It has been repeatedly reported that Tregs accumulate in the tumor microenvironment where they inhibit antitumor immunity in the tumor microenvironment, thereby limiting the efficiency of both spontaneous immune surveillance as well as anticancer immunotherapy. [4] [5] [6] [7] [8] In fact, a correlation has been suggested between tumor-infiltrating Tregs and a poor prognosis. 9 Beyond the accumulation of Tregs in the tumor microenvironment, malignant cells themselves may exert Treg function. [10] [11] [12] Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin's lymphomas derived from T cells that home to and inhabit the skin. Several lines of evidence suggest that the malignant T cells in a subgroup of CTCL patients are Foxp3 þ T cells, and T cells from at least some of these patients suppressed T-cell proliferation in vitro. 13, 14 The notion that patients with Sé zary syndrome, the most common subtype of CTCL, characteristically develop severe immunodeficiency, and thus rather succumb to infections than to disease progression supports the hypothesis that Sé zary syndrome is a malignant proliferation of Tregs. 10 Based on the notion that depletion of Tregs may provoke and enhance tumor immunity, several attempts have been made to deplete Tregs in order to boost spontaneous immune responses or additional immune therapeutic interventions. [15] [16] [17] Unfortunately, there are currently no agents available to specifically inhibit Tregs. Most studies aiming at the depletion of Tregs used either denileukin diftitox, a compound composed of IL-2 fused to a portion of diphtheria toxin that depletes CD25 þ cells, or cyclophosphamide. 9 Clinical trials using a CD25-directed diphtheria toxin (Ontak) to eliminate Tregs have been performed in patients suffering from renal cell carcinoma or melanoma. 18 However, although the first results from the Ontak studies were promising, the full potential of targeting Tregs was probably limited by the unwanted effects on tumor-reactive effector T cells. 19 Cyclophosphamide has been used most extensively to inhibit Tregs, not only because it is widely available and inexpensive, but also because increasing evidence suggests that it exhibits multiple additional immune-modifying properties. 20 Notably, however, the clinical benefit achieved by cyclophosphamide-mediated depletion of Tregs in order to boost immune-modulating therapies seems to be variable. 21, 22 In chronic lymphocytic leukemia, thalidomide exerts antileukemic effects both through reduction of malignant cells and by the killing of Tregs. 23 An attractive attempt to establish a more specific intervention to interfere with Treg-mediated immune suppression was pioneered by Gilboa and colleagues, that is, harnessing the immune system to attack these cells. Indeed, vaccination of mice against Foxp3 induced Foxp3-specific cytotoxic T cells (CTL). These CTL eliminated Foxp3 þ Tregs and thereby enhanced antitumor immunity. 24 Here, we describe spontaneous cytotoxic immune responses to Foxp3-expressing cells in the peripheral blood of healthy volunteers and cancer patients. These CTL are directed against a HLA-A2-restricted peptide epitope derived from Foxp3 and specifically recognize Tregs. Moreover, these cells readily killed Foxp3 þ Sé zary syndrome-derived T-cell lines. The spontaneous presence of Foxp3-specific cytotoxic T-cell responses suggest a general role of such T cells in the complex network of immune regulation as such responses may eliminate Tregs, that is, suppression of the suppressors.
MATERIALS AND METHODS

Patients and healthy donors
Peripheral blood mononuclear cells (PBMC) were collected from melanoma patients, breast cancer patients and healthy controls. Blood samples were drawn a minimum of four weeks after termination of any kind of anticancer therapy. PBMC were isolated using Lymphoprep separation, HLA-typed (Department of Clinical Immunology, University Hospital, Copenhagen, Denmark) and frozen in fetal calf serum with 10% dimethylsulfoxide. The protocol was approved by the Scientific Ethics Committee for The Capital Region of Denmark and conducted in accordance with the provisions of the Declaration of Helsinki. Written informed consent from the patients was obtained before study entry.
Peptides
Epitopes from Foxp3 were predicted using the 'Database SYFPEITHIP' 25 
Enzyme-linked immunosorbent spot assay
In the present study the enzyme-linked immunosorbent spot (ELISPOT) was performed according to the guidelines provided by CIMT Immunoguiding Program (CIP) (http://cimt.eu/cimt/files/dl/cip_guidelines.pdf). In some experiments, PBMC were stimulated once in vitro with peptide before analysis, as indicated, to extend the sensitivity of the assay. 26 Nitrocellulose bottomed 96-well plates (MultiScreen MSIPN4W; Millipore, Hellerup, Denmark) or mixed cellulose ester 96-well plates (MultiScreen MSHAS4B; Millipore) were coated overnight with IFN-g, TNFa or Granzyme B capture mAb (Mabtech, Nacka Strand, Sweden). The wells were washed and then blocked by X-vivo medium and the effector cells were added if possible in quadruplicates, or in triplicates or duplicates, at different cell concentrations, with or without 5 mM peptide. The plates were incubated overnight. The following day, the medium was discarded and the wells were washed before the addition of the relevant biotinylated secondary antibody (Mabtech). The plates were incubated at room temperature for 2 h, washed and avidin-enzyme conjugate (AP-Avidin; Calbiochem/ Invitrogen Life Technologies, Naerum, Denmark) was added to each well. Plates were incubated at room temperature for 1 h and the enzyme substrate nitro-blue tetrazolium chloride/5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt (Invitrogen Life Technologies) was added to each well and incubated at room temperature for 5-10 min. Upon the emergence of dark purple spots, the reaction was terminated by washing with tap water. The spots were counted using the ImmunoSpot Series 2.0 Analyzer (CTL Analyzers, Bonn, Germany).
Mature autologous dendritic cells (DC) were incubated overnight with or without Foxp3 protein (20 mg) (OriGene, Rockville, MD, USA) and used as antigen-presenting cells (APC) in ELISPOT assays (10e4 DC per well).
were used as APC in ELISPOT assays by sorting of the cells directly into coated wells (1e4 T cells per well) after incubation overnight with 1000 U/ml IL-2. Regulatory T cells were also sorted and expanded using high-dose IL-2, and used as APC in ELISPOT assays (1e4-3e4 T cells per well) Sorting was performed on a BD FACS Aria using the antibodies aCD3-PE, aCD4-PerCP, (BD Biosciences, Albertslund, Denmark) aCD127-FITC and aCD25-APC (eBiosciences, San Diego, CA, USA).
Flow cytometry
Tetramer staining was performed in phosphate-buffered saline þ 2% fetal calf serum for 15 min at 37 1C, followed by antibody staining for 30 min on ice. The tetramers were prepared using the MHC-peptide exchange technology as described. 27 The MHC tetramer complexes used were: HLA-A2/ Intracellular staining with aFoxp3-PE (eBiosciences) was performed on expanded Tregs, PBMC, MAC1 and MAC2A cell lines, after fixation and permeabilization (eBiosciences). For comparison, cells were stained with an isotype matched control (eBiosciences).
Staining with aCD107a-FITC (BD Biosciences) was performed by incubation of specific T cells with Foxp3 344-353 peptide and antibody for 4 h followed by tetramer staining as described.
Intracellular cytokine staining was performed by incubation of specific T cells with Foxp3 344-353 peptide and Golgi Plug (BD Biosciences) for 4 h followed by tetramer staining as described, thereafter fixation, permeabilization (eBiosciences) and staining with aIFNg-PE (eBioscience) according to manufacturer's protocol.
Establishment of antigen-specific T-cell cultures
PBMC from a breast cancer patient were stimulated with irradiated (25 Gy) autologous Foxp3 344-353 peptide-loaded DC (PBMC:DC, ratio 10:1). On the same day IL-7 (40 U/ml) and IL-12 (20 U/ml) (PeproTech, London, UK) were added. Stimulation of the cultures with Foxp3 344-353 -loaded irradiated autologous DC were repeated 10 days later followed by addition of IL-12 (20 U/ml) (PeproTech, Stockholm, Sweden) the next day. After an additional 8 days the culture was restimulated with Foxp3 344-353 -loaded irradiated autologous DC once more and IL-2 (20 U/ml) was added after 2 days. One week after the third stimulation, the culture was tested for specificity in a standard 51 Cr-release assay and stained with tetramers for fluorescence activated cell sorting (FACS) analysis.
The culture was further enriched for specific cells by staining of the cells with a HLA-A2/Foxp3 344-353 -PE tetramer followed by isolation of tetramerspecific cells using anti-PE MicroBeads (Miltenyi Biotec, Lund, Sweden). Specific cells were expanded by incubation with 0.6 mg anti-CD3 (eBioscience, clone OKT3) and high-dose IL-2 (Proleukin, Novartis, Copenhagen, Denmark). DC were generated by isolation of monocytes from PBMC by plastic adherence. Monocytes were cultured for 6 days in RPMI-1640 with 10% fetal calf serum with IL-4 (250 U/ml) and GM-CSF (granulocyte macrophage-colony stimulating factor; 1000 U/ml) (PeproTech, Stockholm, Sweden). DC were matured by addition of IL-1b (1000 U/ml), IL-6 (1000 U/ml), TNFa (tumor necrosis factor-a; 1000 U/ml) (PeproTech, Stockholm, Sweden) and PGE 2 (prostaglandin E2; 1 mg/ml) (Cayman Chemical, Ann Arbor, MI, USA).
HLA peptide exchange technology and enzyme-linked immunesorbent assay
To evaluate the affinity of the HLA-peptide complex a ultraviolet (UV) exchange method was used in combination with a sandwich enzymelinked immunosorbent assay as previously described. 27 A strong binding peptide (HLA-A2/HIV-1 pol 476-484 (ILKEPVHGV)) and a sample not exposed Foxp3-specific immunity SK Larsen et al to UV light were used as positive controls, whereas a sample without rescue peptide was used as a negative control. Positive controls were made in quadruplicates and with the Foxp3 344-353 peptide in triplicates.
Cytotoxicity assay Conventional 51
Cr-release assays for CTL-mediated cytotoxicity were carried out as described elsewhere. 28 Target cells were T2 cells with HIV-1 pol 476-484 (ILKEPVHGV) or T2 cells with Foxp3 344-353 , K562 29 , and the Epstein-Barr virus-transformed B-cell line KIG-Bcl 30 or the CTCL cell lines MAC1 and MAC2A. MAC1 and MAC2A are both malignant CTCL cell lines. The two cell lines were established from a HLA-A2 þ patient with progression from lymphomatoid papulosis to systemic anaplastic large cell lymphoma. MAC1 was derived from the blood of the patient, 3 years after progression to systemic anaplastic large cell lymphoma. MAC2A was derived from a skin tumor. 31 
RESULTS
Spontaneous T-cell responses against Foxp3-derived HLA-A2-restricted T-cell epitopes in healthy individuals and cancer patients The ELISPOT assay is a highly sensitive and robust assay that has been utilized for the detection of CD8 þ T-cell responses. 22, 32 Thus, in order to detect CD8 T-cell responses against Foxp3-expressing cells, 15 predicted HLA-A2-restricted T-cell epitopes were synthesized to examine the PBMC from HLA-A2 þ cancer patients using IFN-g ELISPOT assay. The strongest response was observed against the peptide Foxp3 344-353 (TLIRWAILEA) (Figure 1 ). To this end, PBMC from 15 HLA-A2 þ cancer patients and 16 healthy individuals were screened for the presence of specific T-cell responses against this peptide (Figure 1a) . This analysis depicted a strong T-cell reactivity against Foxp3 344-353 in a breast cancer patient (AA21) and weaker responses in four additional cancer patients. In addition, a strong response was detected in a healthy donor (HD202). Nevertheless, a Mann-Whitney test illustrated that there was a significant difference between immune responses in healthy donors and cancer patients (P ¼ 0.01). The strong responses against 
were directly sorted as target for an IFN-g ELISPOT. The Foxp3 344-353 -reactive bulk culture recognized Tregs, whereas conventional CD4 T cells did not elicit a response (Figure 5e ). Figure 5f illustrates the gating strategy for the isolation of conventional CD4 T cells and Tregs, respectively.
One means of CTL-mediated target cell death is the granulemediated pathway via the release of GrB, as the GrB ELISPOT directly determines the release of a cytolytic protein. 34 Thus, as described above, the Foxp3-specific T cells were indeed cytolytic effector cells, as they released GrB in response to Tregs. We were not able to further examine the killing of Tregs by a standard Cr 
DISCUSSION
Any biological system involves negative feedback, and it is now recognized that Tregs are essential in the maintenance of homeostasis of the immune system. 35 Tregs are important regulators of almost all immune responses, for example, modulating host responses to tumors and infections, inhibiting the development of autoimmunity or preventing transplant rejection. Tregs mediate suppressive functions both through the production of cytokines and direct cell-cell contact. 36 Diminished Treg development and function links to autoimmunity, allergy and infectious diseases, whereas elevated Treg cell responses are observed in tumor immunity. Although the immune-modulating mechanisms of Tregs have been scrutinized over the past years, the means by which the immune system controls the function of Tregs is less clear. Here, we provide evidence for a new feedback mechanism to suppress Treg function by identification and characterization of spontaneous cytotoxic T-cell responses against Tregs. We demonstrated that peripheral blood obtained from both healthy donors and cancer patients recognized HLA-restricted peptide epitopes derived from Foxp3, released IFN-g, TNF-a and GrB in response to antigen presented by APC or isolated Tregs, and killed Foxp3-expressing CTCL cell lines.
All nucleated cells express MHC class I molecules, which present peptides derived from endogenous proteins. Naive antigenspecific CD8 þ T cells, however, cannot directly eliminate cells even when specifically reacting with the peptide/MHC complex. To become effector CTL, naive CD8 þ T cells need to be activated first by APCs. When the APCs are not directly expressing the protein from which the respective peptide is derived, they need to acquire an exogenous protein to present them on MHC class I molecules, by a mechanism known as cross-presentation. 37 We proved that Foxp3 is cross-presented by DC, indicating that Foxp3-specific T-cell responses can indeed be readily primed in a number of immune circumstances.
Foxp3 is not the only protein involved in immune regulation that may serve as a target for cytotoxic effector T cells. Similar to the data described here, spontaneous CD8 þ T-cell responses toward epitopes derived from immune regulatory proteins, such as IDO and IDO-2, and very recently PD-L1, have been demonstrated. [38] [39] [40] These are all self-proteins inducible in immune cells under different physiological and/or pathological conditions, for example, inflammation, infection or cancer. Thus, CTL responses may be more widely used to maintain the homeostasis of the immune system than previously anticipated. Notably, the basic regulatory mechanisms employed in the normal development and homeostasis of healthy organisms involves the elimination of certain cells by cytolytic events.
41
Foxp3 is a self-antigen, which is expressed in the thymus, both in thymocytes destined to become Tregs as well as in thymic stromal cells. 42, 43 The apparent lack of tolerance against Foxp3 suggests a more general role of Foxp3-specific cytotoxic T cells in the regulation of the immune system. Hence, Foxp3-specific CTL could have an important role by eliminating regulatory cells thereby suppressing and/or delaying local immune suppression. Indeed, the sizable reactivity toward Foxp3 in a healthy individual (which was directly measurable ex vivo) suggest that this response contributes to immune homeostasis.
Interestingly, in the healthy donor hosting a strong Foxp3 344-353 -specific T-cell response we were not able to stain specific T cells using the HLA-A2/Foxp3 344-353 -tetramer. Naturally, this could be due to a lower sensitivity of the HLA-A2/Foxp3 344-353 -tetramer staining compared with ELISPOT. Several studies have reported that elevated numbers of Tregs in peripheral blood, lymphoid tissues and the tumor itself are associated with poor prognosis. 44 Recently, it was described that levels of peripheral CD4 þ Foxp3 þ Tregs were negatively associated with clinical response to adoptive T-cell therapy in patients with malignant melanoma. 45 As Tregs antagonize the desired effects of immunotherapeutic approaches, their elimination by Foxp3 vaccination would be synergistic with other interventions activating the immune system. In this regard, Nair et al. 24 vaccinated mice with DC transfected with Diminished Treg cell development and function is associated with autoimmunity and allergy, thus one should be especially cautious of the possible introduction of autoimmunity when targeting Foxp3-espressing cells for CTL responses. In this regard it should be noted that neither Nair et al. observed any obvious autoimmune breakthrough events after vaccination against Foxp3, 24 nor did the individuals harboring spontaneous HLA-A2/Foxp3 344-353 responses show any signs of autoimmunity. However, it should be noted that van Es et al. 46 described that vaccination with Foxp3-transfected DC reduced Foxp3 þ Tregs in an atherosclerosis model. Tregs have an important protective role in atherosclerosis and vaccination, leading to an increase in the disease. These data as well as the data presented here further warrant the examination of a potential role of Foxp3-specific CTL in immune regulation and their potential use in different pathogenic settings.
CTCL clinically and biologically represent a heterogeneous group of non-Hodgkin lymphomas. Malignant T cells may not only express Foxp3, but may even function as Tregs. 47 Here, we used Foxp3 þ T-cell lines established from a CTCL patient to demonstrate the cytotoxicity exerted by HLA-A2/ Foxp3 344-353 -reactive CTL. Despite the fact that this strategy was primarily chosen in order to overcome the impracticality to label Tregs with 51 Cr for cytotoxicity assays, it still illustrates that inducing/boosting CTL responses against Foxp3 is an attractive strategy to treat CTCL.
The relevance of immunoregulatory CTL under physiologic and/or pathologic situations in vivo remains to be established in detail, however, the data presented here and reported previously point out that this concept may be more prevalent than anticipated. Elimination of certain cells and tissues is a basic regulatory mechanism employed in the normal development and homeostasis of healthy organisms, thus, the concept that CTL responses are employed for the regulation of the immune system is not surprising. In any case, further exploration of therapeutic possibilities of targeting Tregs by CTL in order to boost immune response to cancer or infections are warranted. 
